Status:
WITHDRAWN
Anti-MERS-CoV Convalescent Plasma Therapy
Lead Sponsor:
King Abdullah International Medical Research Center
Conditions:
Respiratory Distress Syndrome (& [Hyaline Membrane Disease])
Eligibility:
All Genders
14+ years
Phase:
PHASE2
Brief Summary
Since the first report of the Middle East Respiratory Syndrome Corona virus (MERS- CoV) in September 2012, more than 800 cases have been reported to the World Health Organization (WHO) with substantia...
Detailed Description
World knowledge about this virus is accumulating but data about the clinical presentations of infected patients and common treatments, including ribavirin, interferon and methylprednisolone, lack evid...
Eligibility Criteria
Inclusion
- Age greater than or equal to 14 years of age
- Inpatients who are MERS-COV positive (by PCR)
- Willingness to have blood, respiratory and urine samples obtained and stored for subsequent analysis.
Exclusion
- Clinical evidence (in the judgment of the site investigator) that the etiology of illness is primarily not MERS-CoV in origin.
- History of allergic reaction to blood or plasma products (as judged by the investigator)
- Known IgA deficiency
- Medical conditions in which receipt of 500mL volume may be detrimental to the patient (e.g., decompensated congestive heart failure)
- Females who are pregnant or breast feeding.
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02190799
Start Date
May 1 2014
End Date
November 1 2016
Last Update
November 21 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Intensive Care Unit, King Abdulaziz Medical City
Riyadh, Saudi Arabia, 11426